Daiichi Sankyo, Merck Expand Partnership to Develop MK-6070, a Delta-Like Ligand Targeting T-Cell Engager
The collaboration will see both companies jointly develop and commercialize MK-6070 worldwide, except in Japan, where Merck retains exclusive rights.
Image Credit: Adobe Stock Images/hamad
Daiichi Sankyo and Merck announced plans to expand their global collaboration to include MK-6070, a delta-like ligand 3 (DLL3) targeting T-cell engager, in their existing co-development and co-commercialization agreement for three investigational deruxtecan (DXd) antibody-drug conjugates. According to both companies, the deal will see both teams develop and commercialize MK-6070 worldwide outside of Japan, where Merck holds exclusive rights. Moving forward, Merck will take sole responsibility for manufacturing and supply of MK-6070.1
“Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide,” said Ken Takeshita, MD, global head, R&D, Daiichi Sankyo, in a press release. “We look forward to continuing our relationship with Merck with the addition of MK-6070 as it provides potential synergies with our established antibody-drug conjugate collaboration, particularly ifinatamab deruxtecan, and demonstrates our shared commitment to advancing new medicines for patients.”
Currently, the safety, tolerability and pharmacokinetics of MK-6070 is being evaluated in a Phase I/II trial as a monotherapy. Additionally, the companies plan on evaluating MK-6070 in combination with ifinatamab DXd (I-DXd) in certain patients with small cell lung cancer (SCLC) and other combinations. Merck acquired MK-6070 through its acquisition of Harpoon Therapeutics back in March. The FDA granted Orphan Drug Designation to MK-6070 for the treatment of SCLC back in March of 2022.
Under terms of the deal, Merck will receive an upfront cash payment of $170 million, with the companies sharing R&D and commercialization expenses globally. Daiichi Sankyo will receive all royalties based on sales in Japan. As per the original agreement, R&D expenses related to MK-6070 in combination with I-DXd will be shared in a consistent manner.1
SCLC is the most aggressive from of lung cancer, with approximately 30,000 to 35,000 people diagnosed in the United States each year. Today, only 15% of all lung cancers are classified as SCLC. It is most common between the ages of 60-80 years, with men having a slightly higher chance of getting it during their lifetime. Further, 98% of people with the disease have a history of smoking, making it rare for patients who haven’t smoked in their lives. The overall five-year survival rate for people with SCLC is 7%.3
“Small cell lung cancer is an aggressive, fast-growing form of lung cancer and new treatment approaches are urgently needed,” said Dean Y. Li, president, Merck Research Laboratories, in the press release. “We are pleased to build upon our collaboration with Daiichi Sankyo and look forward to evaluating the novel combination of MK-6070 and ifinatamab deruxtecan in small cell lung cancer and other forms of cancer.”
References
1. Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070. Merck. August 6, 2024. Accessed August 6, 2024. https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
2. Merck Completes Acquisition of Harpoon Therapeutics, Inc. Merck. March 11, 2024. Accessed August 6, 2024. https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/
3. Who Gets Small-Cell Lung Cancer? WebMD. July 27, 2022. Accessed August 6, 2024. https://www.webmd.com/lung-cancer/who-gets-small-cell-lung-cancer
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
May 13th 2025Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.
Merck, Lilly Commit Large Investments to US R&D and Manufacturing Expansion
May 12th 2025Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.
Lilly Bolsters ALS Pipeline Through $415 Million Licensing Agreement with Alchemab Therapeutics
May 6th 2025Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly will assume responsibility for further development and commercialization of the novel platform.
